Structure Therapeutics Company Insiders
| GPCR Stock | 19.60 0.37 1.92% |
Structure Therapeutics employs about 183 people. The company is managed by 11 executives with a total tenure of roughly 427 years, averaging almost 38.0 years of service per executive, having 16.64 employees per reported executive. Discussion of Structure Therapeutics' management performance can provide insight into the enterprise performance.
Structure | Build AI portfolio with Structure Stock |
Structure Therapeutics' latest congressional trading
Congressional trading in companies like Structure Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Structure Therapeutics by those in governmental positions are based on the same information available to the general public.
| 2023-11-01 | Senator Thomas R Carper | Acquired Under $15K | Verify |
Structure Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1724) % which means that it has lost $0.1724 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2285) %, meaning that it created substantial loss on money invested by shareholders. Structure Therapeutics' management efficiency ratios could be used to measure how well Structure Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/16/2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to drop to -0.19. At this time, Structure Therapeutics' Total Assets are relatively stable compared to the past year. As of 07/16/2025, Non Current Assets Total is likely to grow to about 12.7 M, while Other Assets are likely to drop 1.09.As of 07/16/2025, Common Stock Shares Outstanding is likely to drop to about 43.8 M. In addition to that, Net Loss is likely to drop to about (41.4 M)
Structure Therapeutics Workforce Comparison
Structure Therapeutics American is rated # 2 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,078. Structure Therapeutics retains roughly 183 in number of employees claiming about 17% of equities under Health Care industry.
Structure Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Structure Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Structure Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Structure Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-09-01 | 1.6667 | 5 | 3 | 218,832 | 24,573 |
| 2025-03-01 | 2.0 | 12 | 6 | 2,823,207 | 27,974 |
| 2024-06-01 | 1.375 | 11 | 8 | 660,889 | 1,137,800 |
| 2024-03-01 | 7.5 | 15 | 2 | 2,050,716 | 22,522 |
| 2023-09-01 | 2.0 | 2 | 1 | 280,500 | 411,000 |
| 2023-03-01 | 1.5714 | 11 | 7 | 6,733,799 | 5,571,649 |
Structure Therapeutics Notable Stakeholders
A Structure Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Structure Therapeutics often face trade-offs trying to please all of them. Structure Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Structure Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jun Yoon | CFO Founder | Profile | |
| Raymond Stevens | CEO Director | Profile | |
| Lani Ibarra | Senior Operations | Profile | |
| Hui Lei | Senior Chemistry | Profile | |
| Xichen Lin | Chief Officer | Profile | |
| Yingli Ma | Chief Officer | Profile | |
| Fang Zhang | Executive Biology | Profile | |
| Blai MD | Chief Officer | Profile | |
| Bob Gatmaitan | Senior People | Profile | |
| Tony Peng | Senior Legal | Profile | |
| Xinglong Jiang | Senior Development | Profile |
About Structure Therapeutics Management Performance
The success or failure of an entity such as Structure Therapeutics often depends on how effective the management is. Structure Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Structure management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Structure management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.14) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.14) | (0.14) | |
| Return On Equity | (0.14) | (0.13) |
Structure Therapeutics Workforce Analysis
Traditionally, organizations such as Structure Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Structure Therapeutics within its industry.Structure Therapeutics Manpower Efficiency
Return on Structure Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 669.5K | |
| Net Loss Per Executive | 11.1M | |
| Working Capital Per Employee | 4.7M | |
| Working Capital Per Executive | 77.7M |
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.